BIAF (bioAffinity Technologies) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 11, 2026)


BIAF bioAffinity Technologies Inc BIAF
44 GF Score
Price $0.76
GF Value $4.27
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioAffinity Technologies Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

bioAffinity Technologies's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BIAF vs NDRA, ISPC, ADVB: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, bioAffinity Technologies's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioAffinity Technologies Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Margin of Safety % (DCF Earnings Based) falls into.


BIAF
44GF Score
bioAffinity Technologies Inc BIAF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is bioAffinity Technologies (BIAF) Overvalued in 2026?

Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued. The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.27. GuruFocus considers bioAffinity Technologies to be Possible Value Trap.

Key valuation signals for BIAF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $4.27 vs. price of $0.76 (82.2% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioAffinity Technologies Business Description

Address 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score

Get the complete analysis for BIAF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price
$4.27
GF Value